
Another Covid-19 antibody cocktail on the menu? Brii Bio touts early win in NIH study for a combo already used in China
Months after flopping in an NIH-sponsored study, Brii Biosciences’ Covid-19 antibody combo has redeemed itself in a second trial.
The biotech says its antibodies — which had hailed from Beijing’s Tsinghua University and Shenzhen Third People’s Hospital — dramatically improved patients’ odds of getting hospitalized or dying over placebo, notching a statistically significant reduction of 78%. That translates to a risk ratio of 0.22 (95% confidence interval: 0.05, 0.86; p<.00001).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.